Status:
WITHDRAWN
The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Myelodysplastic Syndrome
Eligibility:
All Genders
16+ years
Phase:
PHASE1
PHASE2
Brief Summary
To determine the clinical effects of coenzyme Q10 and Curcumin in improving the cytopenias of patients with myelodysplastic syndromes. we propose to explore the efficacy of the natural compounds curcu...
Eligibility Criteria
Inclusion
- MDS patients with RA, RARS or RAEB will be eligible for treatment with CoQ10 as long as their IPSS score ≤ 1.5.
Exclusion
- Pregnant women and nursing women will be excluded.
- History of clinically significant liver or kidney disease.
- ECOG\>2
- IPSS score \>1.5
- Poorly controlled diabetes mellitus, hypertension, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00247026
Start Date
April 1 2007
Last Update
April 11 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel